The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease
Background. Both long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) are widely used in the treatment of chronic obstructive pulmonary disease (COPD). A novel LAMA/LABA combination of umeclidinium/vilanterol (UMEC/VI; 62.5 μg/25 μg) is approved for chronic obstructive pulm...
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Hindawi Limited
2022-01-01
|
| Edice: | Canadian Respiratory Journal |
| On-line přístup: | http://dx.doi.org/10.1155/2022/2878648 |